White House misses deadline for CDC director nominee
Seeking Alpha News (Wed, 25-Mar 4:24 PM ET)
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX) and Biomea Fusion (BMEA)
TipRanks (Wed, 25-Mar 7:40 AM ET)
BioNTech Showcases Late-Stage Lung Cancer Portfolio at ELCC 2026 With Promising Clinical Data
TipRanks (Tue, 24-Mar 5:41 PM ET)
Globe Newswire (Tue, 24-Mar 6:45 AM ET)
Trump administration reportedly shortlisting CDC nominees
Seeking Alpha News (Sat, 21-Mar 12:24 PM ET)
Market Chameleon (Wed, 11-Mar 7:17 AM ET)
Globe Newswire (Tue, 10-Mar 2:48 PM ET)
BioNTech’s Strong Cash Position and Late-Stage Pipeline Set Stage for Pivotal 2026 Milestones
Market Chameleon (Tue, 10-Mar 3:06 AM ET)
BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
Globe Newswire (Tue, 10-Mar 6:45 AM ET)
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Biontech Se - American Depositary Shares trades on the NASDAQ stock market under the symbol BNTX.
As of March 26, 2026, BNTX stock price declined to $88.67 with 129,167 million shares trading.
BNTX has a beta of 0.99, meaning it tends to be less sensitive to market movements. BNTX has a correlation of 0.15 to the broad based SPY ETF.
BNTX has a market cap of $22.29 billion. This is considered a Large Cap stock.
Last quarter Biontech Se - American Depositary Shares reported $1 billion in Revenue and -$.38 earnings per share. This beat revenue expectation by $167 million and exceeded earnings estimates by $.09.
In the last 3 years, BNTX traded as high as $131.52 and as low as $76.53.
The top ETF exchange traded funds that BNTX belongs to (by Net Assets): FBT, IBB, TCAF, FNDF, ARKG.
BNTX has underperformed the market in the last year with a return of -8.6%, while the SPY ETF gained +14.3%. In the last 3 month period, BNTX fell short of the market, returning -6.7%, while SPY returned -5.5%. However, in the most recent 2 weeks BNTX has outperformed the stock market by returning -2.4%, while SPY returned -3.5%.
BNTX support price is $86.54 and resistance is $91.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BNTX shares will trade within this expected range on the day.
